News & Events about Graphite Bio Inc.
Graphite Bio (NASDAQ:GRPH Get Rating) had its target price lowered by Morgan Stanley from $6.00 to $3.00 in a research note released on Friday morning, Benzinga reports. The brokerage currently has an equal weight rating on the stock. Other analysts have also issued research reports about the stock...
BMO Capital Markets downgraded shares of Graphite Bio (NASDAQ:GRPH Get Rating) from an outperform rating to a market perform rating in a report published on Friday, Marketbeat reports. BMO Capital Markets currently has $7.00 price target on the stock, down from their previous price target of...
Graphite Bio's (NASDAQ:GRPH) short percent of float has fallen 3.92% since its last report. The company recently reported that it has 1.25 million shares sold short, which is 5.64% of all regular shares that are available for trading.
read more...
Shares of Graphite Bio, Inc. (NASDAQ:GRPH Get Rating) have been assigned a consensus rating of Moderate Buy from the seven research firms that are currently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating and four have...
Business Wire
2 months ago
Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases, today presented preclinical results supporting the use of a single-cell...